Thermo Fisher had in July sweetened its offer, valuing the company at 11.3 billion euros ($13.38 billion) after pressure from some Qiagen investors, particularly after the German firm said it was seeing strong demand for products related to coronavirus testing. Thermo Fisher said the number of Qiagen shares tendered into the offer fell short of its threshold of 66.67%. As part of the sweetened offer, Thermo Fisher had reduced the minimum acceptance threshold from 75% of outstanding ordinary share capital. …read more
Source:: Yahoo Finance
